Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
absorption, andProctocort, automatic, CD, Crohn, dissolution, EIR, fasted, fed, Hatch, healthy, hepatology, Nonrecurring, pK, plasma, prefilled, stay, suit, syringe, TD, vitro, Wassermann, Waxman
Removed:
Arcolab, ensuing, permission, submit, Suitability, suitable
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.95 Amended & Restated License Agreement
- 10.96 Eir Supply Agreement
- 10.97 Amendment NO.2 to Supply Agreement
- 10.98 Trademark License Agreement
- 10.99 Trademark License Agreement
- 10.100 Letter Amendment
- 31.1 Section 302 CEO Certification
- 31.2 Section 302 CFO Certification
- 32.1 Section 906 CEO Certification
- 32.2 Section 906 CFO Certification
Related press release
Salix Pharmaceuticals similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Salix Pharmaceuticals, Ltd. (the “Company”) for the period ended September 30, 2012 as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Carolyn J. Logan, President and Chief Executive Officer, hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report. |
Date: November 8, 2012 | By: | /s/ Carolyn J. Logan | ||||
Carolyn J. Logan | ||||||
President and Chief Executive Officer |